EA201690600A1 - Метаболически оптимизированная клеточная культура - Google Patents

Метаболически оптимизированная клеточная культура

Info

Publication number
EA201690600A1
EA201690600A1 EA201690600A EA201690600A EA201690600A1 EA 201690600 A1 EA201690600 A1 EA 201690600A1 EA 201690600 A EA201690600 A EA 201690600A EA 201690600 A EA201690600 A EA 201690600A EA 201690600 A1 EA201690600 A1 EA 201690600A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell culture
proteins
optimized cell
present
polypeptides
Prior art date
Application number
EA201690600A
Other languages
English (en)
Other versions
EA033783B1 (ru
Inventor
Шон Лоуренс
Энн Ким
Эми Джонсон
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690600(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201690600A1 publication Critical patent/EA201690600A1/ru
Publication of EA033783B1 publication Critical patent/EA033783B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Abstract

Предусмотрен улучшенный способ крупномасштабного получения белков и/или полипептидов в клеточной культуре. Согласно настоящему изобретению способ предусматривает культивирование клеток, в которых произошел метаболический сдвиг. Применение такого способа или системы обеспечивает высокие уровни производства белка или полипептида и снижает накопление такого нежелательного отхода метаболизма, как лактат. Белки и полипептиды, экспрессированные согласно настоящему изобретению, могут успешно применяться в получении фармацевтических, иммуногенных или других коммерческих биологических композиций, таких как антитела.
EA201690600A 2013-10-11 2014-10-10 Метаболически оптимизированная клеточная культура EA033783B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361889815P 2013-10-11 2013-10-11
PCT/US2014/059993 WO2015054554A1 (en) 2013-10-11 2014-10-10 Metabolically optimized cell culture

Publications (2)

Publication Number Publication Date
EA201690600A1 true EA201690600A1 (ru) 2016-09-30
EA033783B1 EA033783B1 (ru) 2019-11-25

Family

ID=52813657

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201991976A EA201991976A1 (ru) 2013-10-11 2014-10-10 Метаболически оптимизированная клеточная культура
EA201690600A EA033783B1 (ru) 2013-10-11 2014-10-10 Метаболически оптимизированная клеточная культура

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201991976A EA201991976A1 (ru) 2013-10-11 2014-10-10 Метаболически оптимизированная клеточная культура

Country Status (18)

Country Link
US (2) US20160244725A1 (ru)
EP (3) EP3812453A1 (ru)
JP (3) JP6663854B2 (ru)
KR (4) KR102510238B1 (ru)
CN (2) CN105637085A (ru)
AU (2) AU2014331776B2 (ru)
CA (1) CA2926049C (ru)
DK (2) DK3351620T3 (ru)
EA (2) EA201991976A1 (ru)
ES (2) ES2678945T3 (ru)
HK (2) HK1223122A1 (ru)
HU (2) HUE039551T2 (ru)
IL (2) IL244511A0 (ru)
MX (2) MX2016004564A (ru)
PL (2) PL3055409T3 (ru)
SG (2) SG11201601681QA (ru)
WO (1) WO2015054554A1 (ru)
ZA (1) ZA201601550B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102510238B1 (ko) 2013-10-11 2023-03-16 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
US20160244726A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
JP7260011B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260020B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260018B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7310947B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7272480B2 (ja) * 2017-04-27 2023-05-12 株式会社三洋物産 遊技機
JP7260021B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310945B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260012B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310952B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260009B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260013B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
CN111344558A (zh) 2017-10-06 2020-06-26 龙沙有限公司 使用拉曼光谱法自动控制细胞培养
EP4039786A1 (en) 2017-10-16 2022-08-10 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
US20200385673A1 (en) * 2017-11-30 2020-12-10 Hoffmann-La Roche Inc. Process for culturing mammalian cells
GB201810772D0 (en) * 2018-06-29 2018-08-15 Ge Healthcare Bio Sciences Ab Method in bioprocess purification system
JP2020151559A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP2020151560A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6165741A (en) 1997-05-30 2000-12-26 The Trustees Of The University Of Pennsylvania Method for rapid detection of bacterial growth in cultures
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
DE60211329T2 (de) 2001-01-16 2007-05-24 Regeneron Pharmaceuticals, Inc. Isolierung von sezernierte proteine exprimierenden zellen
US6953692B2 (en) * 2001-12-18 2005-10-11 Bayer Pharmaceuticals Corporation Device and method for seed-train expansion of mammalian cells
US7039770B1 (en) 2002-03-05 2006-05-02 Juniper Networks, Inc. Low latency request dispatcher
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ES2344789T5 (es) 2003-05-15 2017-06-14 Wyeth Llc Alimentación restringida de glucosa para el cultivo de células animales
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
EP1943333A2 (en) * 2005-11-02 2008-07-16 Wyeth a Corporation of the State of Delaware Methods for adapting mammalian cells
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7575890B2 (en) 2006-01-18 2009-08-18 Oxygen Enterprises, Ltd. Method for rapid detection and evaluation of cultured cell growth
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
EP2150617B1 (en) 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP3327132A3 (en) 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US20090325287A1 (en) * 2008-06-13 2009-12-31 Haimanti Dorai Methods for Obtaining High Viable Cell Density in Mammalian Cell Culture
US8470552B2 (en) * 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
SG185038A1 (en) * 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
WO2011150241A2 (en) * 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
TWI637057B (zh) 2012-11-09 2018-10-01 拜爾沙納有限公司 具交替生物反應器用途之不連續進料批次製程
KR102510238B1 (ko) 2013-10-11 2023-03-16 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양

Also Published As

Publication number Publication date
KR20160062032A (ko) 2016-06-01
DK3351620T3 (da) 2020-10-26
CN105637085A (zh) 2016-06-01
ES2833471T3 (es) 2021-06-15
SG10201800772TA (en) 2018-03-28
ZA201601550B (en) 2023-05-31
AU2014331776B2 (en) 2020-10-22
CN114717196A (zh) 2022-07-08
JP7377243B2 (ja) 2023-11-09
KR20230038324A (ko) 2023-03-17
KR20220020415A (ko) 2022-02-18
EP3055409A4 (en) 2016-09-28
KR20210046835A (ko) 2021-04-28
JP2016532457A (ja) 2016-10-20
AU2021200193A1 (en) 2021-03-18
MX2016004564A (es) 2016-07-12
DK3055409T3 (en) 2018-07-30
HK1223122A1 (zh) 2017-07-21
US20210087535A1 (en) 2021-03-25
KR102243980B1 (ko) 2021-04-26
EP3055409B1 (en) 2018-04-25
KR102358807B1 (ko) 2022-02-08
IL262833A (en) 2018-12-31
ES2678945T3 (es) 2018-08-21
JP6663854B2 (ja) 2020-03-13
EP3812453A1 (en) 2021-04-28
PL3055409T3 (pl) 2018-10-31
EA033783B1 (ru) 2019-11-25
AU2014331776A1 (en) 2016-03-24
EP3351620A1 (en) 2018-07-25
KR102610425B1 (ko) 2023-12-06
CA2926049A1 (en) 2015-04-16
EA201991976A1 (ru) 2020-04-02
EP3351620B1 (en) 2020-09-02
US20160244725A1 (en) 2016-08-25
IL244511A0 (en) 2016-04-21
HUE051049T2 (hu) 2021-01-28
EP3055409A1 (en) 2016-08-17
CA2926049C (en) 2023-09-05
JP2022009453A (ja) 2022-01-14
AU2021200193B2 (en) 2023-08-24
JP2020072760A (ja) 2020-05-14
HK1253275A1 (zh) 2019-06-14
KR102510238B1 (ko) 2023-03-16
MX2020011334A (es) 2021-07-30
PL3351620T3 (pl) 2021-03-08
HUE039551T2 (hu) 2019-01-28
WO2015054554A1 (en) 2015-04-16
JP6967620B2 (ja) 2021-11-17
SG11201601681QA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
EA201690600A1 (ru) Метаболически оптимизированная клеточная культура
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
EA201692498A1 (ru) Способы сбора культур клеток млекопитающих
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
SG10201809146QA (en) Recombinant host cell engineered to overexpress helper proteins
EA201691297A1 (ru) Среда для культивирования клеток
SG10201809152QA (en) Recombinant host cell for expressing proteins of interest
MX2019003427A (es) Composiciones para cultivo celular y metodos para la produccion de polipeptidos.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
WO2011091350A3 (en) Methods & compositions for improving protein production
EA201492183A1 (ru) Клетки для получения рекомбинантной идуронат-2-сульфатазы
EA201491144A1 (ru) Способ флокуляции
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
MX2016005824A (es) Metodo de cultivo celular.
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
EA201490945A1 (ru) Набор, содержащий заменитель сыворотки и лабильные факторы
MX357655B (es) Mediador soluble.
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
EA201992828A1 (ru) Способы культивирования клеток
MX2015010887A (es) Formulaciones y metodos para aumentar la produccion de proteinas recombinantes.
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
EA201692263A1 (ru) Совместное культивирование пропионобактерий и дрожжей
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AM AZ BY KZ KG TJ TM RU